US-based firm MSD has announced its intends to acquire biopharma firm Tilos Therapeutics, and has signed a deal with the company to this effect, valued to a total of $773 million.
This new deal means that MSD will acquire all outstanding shares of Tilos through a subsidiary, which altogether come to a potential consideration of $773 million, which includes both an upfront payment as well as milestone payments dependent on the achievement of certain developmental and commercial goals.
